December 14, 2017 12:07 PM ET


Company Overview of R-Pharm JSC

Company Overview

R-Pharm JSC, a pharmaceutical company, researches, develops, manufactures, markets, sells, and distributes pharmaceutical products. It engages in the manufacture of finished dosage forms, active pharmaceutical ingredients of chemical nature, and biotech substances; research and development of innovative products and technologies; and implementation of education and training programs for pharmaceutical and healthcare industries. The company’s portfolio includes medicinal products of various pharmaceutical groups, including oncology, hematology, cardiology, immunology, antibacterial, and anti-viral, including the treatment of HIV-infection; and medicinal products used in organ transplantation,...


Leninskiy prospect

Moscow,  119421


Founded in 2001


7 495 956 7937


7 495 956 7938

Key Executives for R-Pharm JSC

Chief Executive Officer and Director
Chief Operating Officer, Chief Commercial Officer and Executive Director
Chief Scientific Officer of R-Pharm Overseas, Inc and CEO of R-Pharm Overseas, Inc
Head of Customer Service Section
Chief Medical Officer
Compensation as of Fiscal Year 2017.

R-Pharm JSC Key Developments

R-Pharm JSC Presents at St. Petersburg International Economic Forum 2017 Programme, Jun-03-2017 10:00 AM

R-Pharm JSC Presents at St. Petersburg International Economic Forum 2017 Programme, Jun-03-2017 10:00 AM. Venue: St. Petersburg, Russia. Speakers: Vasily Ignatiev, Chief Executive Officer and Director.

R-Pharm JSC Presents at Russian Pharmaceutical Forum, May-16-2017 through May-17-2017

R-Pharm JSC Presents at Russian Pharmaceutical Forum, May-16-2017 through May-17-2017. Venue: Corinthia Saint-Petersburg Hotel, 57 Nevskij Prospect, St. Petersburg 191025, Russia. Presentation Date & Speakers: May-16-2017, Alexey Repik, Chairman of the Board, Vasily Ignatiev, Chief Executive Officer and Director. May-17-2017, Aleksandr Bykov, Health Economics Director.

Mitsui & Co. Seeks Investment In Ros Agro And R-Pharm

Mitsui & Co., Ltd. (TSE:8031) seeks to invest in Ros Agro PLC (LSE:AGRO) and R-Pharm JSC. Mitsui & Co. and Ros Agro will sign a memorandum of understanding on a capital and business tie-up. Mitsui & Co. is expected to invest several billion yen in Ros Agro. The trading house is also expected to spend ¥15 billion to ¥20 billion ($130 million to $174 million) for a roughly 10% stake in R-Pharm JSC. The partnership with Mitsui & Co. will let it handle a broader range of drugs and expand overseas sales channels.

Similar Private Companies By Industry

Company Name Region
Aknol Europe
Alfarm, Ooo Europe
Angelico Pharmaceuticals Europe
AO Medisorb Europe
Biomed Im. I.I. Mechnikova, AO Europe

Recent Private Companies Transactions

April 14, 2017
December 16, 2016

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact R-Pharm JSC, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at